関: pranlukast hydrate

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/12/06 09:03:11」(JST)

wiki en

Pranlukast is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s Singulair (montelukast). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective.

References[edit]

^ ^a ^b Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma.". Drug Metab Pharmacokinet 21 (2): 133–9. doi:10.2133/dmpk.21.133. PMID 16702733.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 喘息の治療において5-リポキシゲナーゼ経路に影響する薬剤 agents affecting the 5 lipoxygenase pathway in the treatment of asthma
2. 思春期および成人における中等度持続型喘息の治療 treatment of moderate persistent asthma in adolescents and adults
3. 好酸球性肉芽腫性多発血管炎(チャーグ・ストラウス症候群）の疫学、病因、および病理 epidemiology pathogenesis and pathology of eosinophilic granulomatosis with polyangiitis churg strauss
4. 慢性蕁麻疹：標準的なマネージメントおよび患者教育 chronic urticaria standard management and patient education

English Journal

A co-module approach for elucidating drug-disease associations and revealing their molecular basis.

Zhao S, Li S.SourceMOE Key Laboratory of Bioinformatics and Bioinformatics Division, TNLIST/Department of Automation, Tsinghua University, Beijing, China.
Bioinformatics (Oxford, England).Bioinformatics.2012 Apr 1;28(7):955-61. Epub 2012 Jan 28.
MOTIVATION: Understanding how drugs and diseases are associated in the molecular level is of critical importance to unveil disease mechanisms and treatments. Until recently, few studies attempt end to discover important gene modules shared by both drugs and diseases.RESULTS: Here, we propose a novel
PMID 22285830

Impact of add-on pranlukast in stable asthma; the additive effect on peripheral airway inflammation.

Yasui H, Fujisawa T, Inui N, Kato M, Hashimoto D, Enomoto N, Nakamura Y, Shirai T, Suda T, Nakamura H, Chida K.SourceSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. yassy19781119@yahoo.co.jp
Respiratory medicine.Respir Med.2012 Apr;106(4):508-14. Epub 2012 Jan 21.
BACKGOUND: The importance of airway inflammation has been highlighted in the pathophysiology of asthma. Even in controlled asthmatics treated with inhaled corticosteroid (ICS), residual airway inflammation is reported. Systemic therapy with oral leukotriene receptor antagonist, pranlukast, may have
PMID 22265857

Japanese Journal

臨床研究・症例報告プランルカストが有効であった抗ヒスタミン薬抵抗性慢性特発性蕁麻疹の1男児例

櫻井嘉彦,西山敦子,薮本仁美 [他]
小児科臨床 68(1), 103-108, 2015-01
NAID 40020304923

プランルカスト水和物の経口持続性製剤化を目指した胃内滞留性製剤の設計に関する研究

杉原光,竹内洋文,スギハラヒカル,タケウチヒロフミ,Hikaru SUGIHARA,Hirofumi TAKEUCHI
岐阜薬科大学紀要　 = The annual proceedings of Gifu Pharmaceutical University 63, 1-10, 2014-06-30
… In a human site-of-absorption study pranlukast hydrate was demonstrated to have extremely poor absorption properties inthe lower gastrointestinal tract. …
NAID 120005564609

Cysteinyl leukotriene receptor antagonist regulates allergic airway inflammation in an organ- and cytokine-specific manner

Kawano Tetsuya,Matsuse Hiroto,Tsuchida Tomoko,Fukahori Susumu,Fukushima Chizu,Nishino Tomoya,Kohno Shigeru
Medical Science Monitor 20, 297-302, 2014-02-22
… pranlukast (Prl), an LTRA-treated AS; …
NAID 120005438870

Related Pictures

★リンクテーブル★

リンク元	「プランルカスト」
拡張検索	「pranlukast hydrate」

「プランルカスト」

Pranlukast
Systematic (IUPAC) name
	N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-7-yl]-4-(4-phenylbutoxy)benzamide
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy cat.	?
Legal status	?
Routes	Oral
Pharmacokinetic data
Metabolism	Hepatic (mainly CYP3A4)
Half-life	1.5 hours
Identifiers
CAS number	103177-37-3
ATC code	R03DC02
PubChem	CID 4887
DrugBank	DB01411
ChemSpider	4718
UNII	TB8Z891092
ChEMBL	CHEMBL21333
Chemical data
Formula	C27H23N5O4
Mol. mass	481.503 g/mol
	SMILES O=C(c2ccc(OCCCCc1ccccc1)cc2)Nc5cccc3c5O/C(=C\C3=O)c4nnnn4;
	InChI InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) ; Key:NBQKINXMPLXUET-UHFFFAOYSA-N ;
(what is this?) (verify);